Randomized Trialhigh evidence
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
The New England journal of medicine·March 12, 2026·PMID 41812192
Why it mattersDirect oral anticoagulants are first-line for acute VTE, but real-world bleeding differences remain uncertain. This head-to-head trial provides strong evidence that apixaban may offer a safer bleeding profile than rivaroxaban during initial treatment.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled